Uncategorized
Ready-diluted formulation of Jetrea receives positive opinion in European Union
The Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for a ready-diluted formulation of Jetrea, according to a press release from ThromboGenics.Jetrea (ocriplasmin) is approved in the European Union for the treatment of vitreomacular traction (VMT). The new formulation is designed to eliminate the preparatory dilution steps before injection.